All In Biotech

Drug Trial Radar · NCT07318610

Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, in Participants With Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease (ROXI-PALISADE)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 7,050 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

7,050

Planned (sponsor's estimate)

Start

Jul 10, 2026

Primary completion

Aug 18, 2029

Study completion Nov 16, 2029

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jan 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become too narrow. People with PAD have a higher risk of getting blood clots after procedures like Lower Extremity Revascularization (LER), a procedure to improve blood flow in the legs and feet. The aim of this study is to see how well REGN7508 and REGN9933 prevent life-threatening blood clots in participants with PAD who have recently had LER. The effects of REGN7508 and REGN9933, individually, will also be compared to rivaroxaban and a placebo. The study is looking at several other research questions, including: * What side effects might happen from taking the study drugs and how do they compare to the side effects of rivaroxaban * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects) * If the study drugs affect the ability of the blood to clot normally

Conditions

  • Peripheral Artery Disease (PAD)

Interventions

  • REGN7508Drug

    Administered per the protocol

  • REGN9933Drug

    Administered per the protocol

  • PlaceboDrug

    Administered per the protocol

  • RivaroxabanDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time-to-first occurrence of a major thrombotic vascular event, consisting of Acute Limb Ischemia (ALI), major amputation (above the ankle) of vascular etiology, Myocardial Infarction (MI), ischemic stroke, or Cardiovascular (CV) deathTime frame: Approximately up to 42 months
  2. Time-to-first occurrence of International Society of Thrombosis and Hemostasis (ISTH) major or Clinically Relevant Non-major (CRNM) bleedingTime frame: Approximately up to 42 months

Locations

34 sites in 3 countries. Site status is shown where the registry gives one.

  • Advanced Cardiovascular

    Alexander City, Alabama · Recruiting

  • Lake Martin Medical and Vascular Center

    Alexander City, Alabama · Recruiting

  • Axsendo Clinical Research, Integrated Medical Services

    Avondale, Arizona · Recruiting

  • Applied Research Center of Arkansas

    Little Rock, Arkansas · Recruiting

  • Angel City Research, Inc.

    Los Angeles, California · Recruiting

  • Pacific Cardiovascular and Vein Institute

    Oxnard, California · Recruiting

  • Interventional Cardiology Medical Group

    West Hills, California · Recruiting

  • Nature Coast Clinical Research - Cardiology

    Crystal River, Florida · Recruiting

  • University of Florida (UF) Health Jacksonville Clinical Center

    Jacksonville, Florida · Recruiting

  • Inpatient Research Clinic LLC

    Miami Lakes, Florida · Recruiting

  • Cardiovascular Institute of Northwest Florida, Main Office

    Panama City, Florida · Recruiting

  • Tampa Cardiovascular Interventions and Research

    Tampa, Florida · Recruiting

  • Lutheran Medical Group LLC dba Lutheran Health Physicians

    Fort Wayne, Indiana · Recruiting

  • ASHA Clinical Research Munster, LLC

    Hammond, Indiana · Recruiting

  • Profound Research, Powers Health Medical Group

    Munster, Indiana · Recruiting

  • Cardiovascular Solutions

    Shreveport, Louisiana · Recruiting

  • Rovia Clinical Research - Hattiesburg Clinic

    Petal, Mississippi · Recruiting

  • Advanced Heart and Vascular Institute of Hunterdon

    Flemington, New Jersey · Recruiting

  • Westchester Medical Center

    Valhalla, New York · Recruiting

  • Mecklenburg Heart Specialists Vascular Institute and Vein Center

    Charlotte, North Carolina · Recruiting

  • Accellacare of Piedmont, Piedmont Healthcare

    Mooresville, North Carolina · Recruiting

  • Hightower Clinical

    Oklahoma City, Oklahoma · Recruiting

  • Monument Health Clinical Research

    Rapid City, South Dakota · Recruiting

  • Apex Research Foundation, LLC

    Jackson, Tennessee · Recruiting

  • Tennova TCMC

    Knoxville, Tennessee · Recruiting

  • Vanderbilt Heart and Vascular Tullahoma, Cardiology and Vascular Associates

    Tullahoma, Tennessee · Recruiting

  • PharmaTex Research

    Amarillo, Texas · Recruiting

  • Vital Heart and Vein

    Cypress, Texas · Recruiting

  • Epic Medical Research

    DeSoto, Texas · Recruiting

  • Epic Medical Research-Plano

    Plano, Texas · Recruiting

  • Kita Harima Medical Center

    Ono-shi, Hyōgo, Japan · Recruiting

  • Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust

    Doncaster, United Kingdom · Recruiting

  • Charing Cross Hospital

    London, United Kingdom · Recruiting

  • Manchester Royal Infirmary

    Manchester, Greater Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.